Bio-Rad Laboratories, Inc. filings document operating results, governance, capital structure, and material events for a Delaware company that develops, manufactures, and markets life science research and clinical diagnostics products.
Form 8-K reports furnish quarterly and annual earnings releases, supplemental earnings materials, Regulation FD presentations, Droplet Digital PCR product-portfolio disclosures, and updates related to the company’s investment in Sartorius AG. Proxy materials cover board elections, executive compensation, shareholder voting matters, governance practices, and Class A and Class B common stock disclosures.
Bio-Rad Laboratories, Inc. EVP, General Counsel & Sec Courtney C. Enloe reported a direct sale of 902 shares of Bio-Rad A Common Stock on November 10, 2026, at $386.165 per share. After the sale, her reported direct holdings were approximately 750 shares.
Bio-Rad Laboratories, Inc. President & COO Jonathan P. DiVincenzo reported a direct sale of 919 shares of Bio-Rad A Common Stock on November 9, 2026, for $390.47 per share. His reported position after the sale was 1,962 shares held directly.
BIO-RAD LABORATORIES, INC. EVP, President, LSG James Barry sold 1,400 shares of Bio-Rad A Common Stock on November 9, 2026, at a weighted-average price of $385.626 per share. The footnote says the shares were sold in multiple transactions priced from $385.588 to $385.645 per share. He directly held 625 shares after the sale.
Courtney Enloe, an officer of BIO-RAD LABORATORIES, INC., listed a proposed sale of 902 common shares, with an aggregate market value of $348,320.83 and an approximate sale date of November 10, 2026. Morgan Stanley Smith Barney LLC is named as broker. The shares were acquired from the issuer as restricted stock: 439 shares on September 5, 2026, and 463 shares on September 6, 2026.
BIO-RAD LABORATORIES, INC. officer Jonathan DiVincenzo reported a proposed sale of 919 common shares, with an aggregate market value of $358,841.93 and an approximate sale date of November 9, 2026. Morgan Stanley Smith Barney LLC is listed as the broker. The shares are identified as restricted stock acquired from the issuer on October 24, 2025.
Bio-Rad Laboratories, Inc. officer James Barry reported a proposed sale of 1,400 common shares, with an aggregate market value of $539,876.82. The approximate sale date is November 9, 2026, through Morgan Stanley Smith Barney LLC; the notice names the NYSE as the exchange. The shares are reported as restricted stock acquired from the issuer in three entries: 156 on September 1, 658 on September 5, and 586 on September 6, 2026. Bio-Rad Laboratories, Inc. had 21,832,130 shares outstanding.
Bio-Rad Laboratories, Inc. reported third-quarter 2026 net sales of $656.4 million and net income of $458.6 million, compared with $653.0 million of sales and a $341.9 million net loss a year earlier. Results included a $583.2 million holding gain on its Sartorius investment. Income from operations was a $49.7 million loss, including a $49.8 million impairment of Celsee-related intangible assets.
For the first nine months, net sales were $1,899.5 million versus $1,890.0 million, while currency-neutral sales declined 1.7%. Net cash provided by operating activities was $303.2 million, compared with $367.3 million. Third-quarter gross margin was 50.1%, compared with 52.6%, and SG&A expense was $257.1 million, compared with $206.8 million.
The July 2026 restructuring plan recorded $77.6 million in costs through September 30. Total pre-tax costs are expected to be approximately $80 million to $90 million, and annual operating expenses are expected to decline by $30 million to $35 million by the end of 2027 once the plan is fully implemented. The plan is expected to be substantially completed by the end of fiscal 2027.
Bio-Rad Laboratories, Inc. reported third-quarter 2026 net sales of $656.4 million, up 0.5% reported and 0.7% currency-neutral year over year. Clinical Diagnostics sales were $401.8 million, up 2.8% currency-neutral; Life Science sales were $254.6 million, down 2.4% currency-neutral.
GAAP net income was $458.6 million, versus a $341.9 million loss a year earlier; Bio-Rad said the fair-market-value change in its Sartorius AG investment substantially contributed. Non-GAAP net income was $71.5 million versus $60.8 million, and non-GAAP operating income was $83.7 million versus $77.0 million. Non-GAAP gross margin was 54.5%, compared with 53.5%; non-GAAP operating margin was 12.8%, compared with 11.8%. GAAP operating loss was $49.7 million, including $77.2 million in restructuring costs and a $49.8 million non-cash impairment charge.
Net cash from operations was $96.4 million, compared with $120.9 million; free cash flow was $65.2 million versus $89.2 million. For 2026, Bio-Rad expects non-GAAP currency-neutral revenue from an approximately 3.0% decline to approximately 0.5% growth, and non-GAAP operating margin of approximately 10.0% to 12.0%.
BIO-RAD LABORATORIES, INC. President & COO Jonathan P. DiVincenzo acquired 1,869 shares of Bio-Rad Class A common stock on October 24, 2026, as restricted stock units vested. On the same date, 951 shares were delivered or withheld for payment of exercise price or tax liability at $369.95 per share. The reported post-transaction position was 3,740 restricted stock units.
At Bio-Rad Laboratories, Inc., EVP, Global Supply Chain Sedat Evran reported vesting of 1,044 restricted stock units into 1,044 shares of Bio-Rad Class A common stock on October 20, 2026. Also on that date, 487 shares were delivered or withheld for payment of exercise price or tax liability, at a reported price of $354.50 per share. The derivative entry lists 1,044 restricted stock units following the transaction.